$RWAY

Top Specialty Finance Stock Pick from B Riley Securities

Investing.com reports B Riley Securities reiterated a Buy on specialty finance company Runway Growth Finance (RWAY) for 2026 and raised its price target to $11 from $10. The target follows Q2 2026 results, including net investment income per share of $0.43 vs $0.26 estimate, revenue of $37.03 million, and NAV per share down 2% to $11.91.

Original reporting
Published Aug 17, 2026, 12:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RWAY
Bullish
medium confidence
Mentioned
$RWAY
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$RWAYBullishLow
01

Why it matters

For RWAY, the immediate tradable element is the PT increase to $11 and the reiteration of a Buy, justified by Q2 net investment income per share beating estimates and revenue exceeding forecasts, plus adviser buyback activation after a blackout lift.

02

Market read

This is primarily an analyst-driven catalyst anchored to reported Q2 metrics and buyback activation, likely to influence short-term positioning more than fundamentals.

03

What to watch

The article emphasizes adviser/board buyback activation and dividend yield, but does not quantify how much of the earnings strength is sustainable versus acquisition timing, fee reversals, and one-time transaction costs.

Relevance 4/10Novelty 4/10Timing: today’s analyst note, tied to the week-ahead watchlist

Background

The piece is a week-ahead market watch item that highlights B Riley Securities’ top specialty finance pick for 2026.

Company-level read

Ticker impact

$RWAYBullishMedium confidence
Context

B Riley reiterates a Buy on Runway Growth Finance and raised its price target to $11 from $10 after Q2 results beat estimates.

Expected impact

Mild positive bias for the next few sessions, with follow-through dependent on whether the market treats the Q2 beat as fresh information versus already-known.

Evidence & confidence

The newest actionable items are the PT change and the firm’s framing of NAV, risk rating, and adviser buyback activation after the blackout lift; the underlying earnings details are the primary factual driver, but the article is not a direct company filing.

Market effects

Supports sentiment for specialty finance/business development companies via a positive read-through on earnings quality and NAV/risk metrics.

No specific regional catalyst beyond US specialty finance sentiment.

Limited, as the story is company-specific and analyst-driven.

Counterpoint

Despite the Q2 beat, NAV per share declined and realized-loss conversions (Marley Spoon, Blueshift) could pressure future earnings quality or NAV stability.

Key entities

  • Runway Growth Finance

    Specialty finance/business development company highlighted as B Riley’s preferred pick, with a raised $11 price target after Q2 results.

  • B Riley Securities

    Broker-dealer that reiterated Buy and increased its price target based on Q2 performance and NAV/risk metrics.

Related articles

$RWAYMedAI 8/10

Runway Growth Q2 2026 slides: SWK deal drives 71% NII jump

Runway Growth Finance Corp. (RWAY) released Q2 2026 investor slides on Aug. 7, citing the April 6 SWK Holdings acquisition as a driver of results. Net investment income rose 71.7% to $18.2M ($0.43/share). Total investment income rose to $37.0M. NAV per share fell to $11.91 after $8.1M transaction expenses. Shares rose 13.21% to $6.77.

$RWAYMed

Runway Growth Finance Corp. (RWAY): Results of Operations and Financial Condition

Runway Growth Finance Corp. (RWAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Runway Growth Finance Corp. Reports Second Quarter 2026 Financial Results Delivered Total and Net Investment Income of $37.0 million and $18.2 million, Respectively Investment Portfolio of $1.2 billion Conference Call on Friday, August 7, 2026 at 10:00 a.m. ET MENLO PARK, Calif.,

$RWAYMed

Runway Growth Finance Corp. Provides Second Quarter 2026 Business and Portfolio Update

Runway Growth Finance Corp. (Nasdaq: RWAY) reported a Q2 2026 business and portfolio update for the quarter ended June 30, 2026. The company said adviser and affiliates plan to buy up to 10% of outstanding shares if trading remains below 70% of NAV, and it has a $15.0 million repurchase authorization. Q2 funded $85.8 million in new and existing investments and reported $36.5 million in liquidity events.

$RWAYMed

Bulldog Investors Calls on Runway Growth Finance Corp. (RWAY) to Expand Its Share Repurchase Program

Bulldog Investors, a >3% shareholder of Runway Growth Finance Corp. (RWAY), urged management to materially expand RWAY’s share repurchase program. It cites RWAY’s May 7 $15m buyback at $6.83 and subsequent decline to $5.49 by July 2, with shares trading ~55% below last reported NAV ($12.13). Bulldog also asks for reduced debt and warns it may nominate directors.

$RWAYMed

Is Runway Growth Finance (RWAY) One of the Top 10 Dividend Stocks with 10%+ Yield?

BofA downgraded Runway Growth Finance (RWAY) to Underperform from Neutral and cut its price target to $5.50 from $9, citing ongoing earnings pressure, higher non-accruals, and declining NAV per share, with expectations of further dividend reset. RWAY reported Q1 2026 total investment income of $29.5M and net investment income of $10.6M; two loans moved to nonaccrual.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.